Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulzerasib for KRAS G12C-mutant advanced NSCLC (observational effectiveness and safety study)
ChiCTR2500106513Phase 4Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fulzerasib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500106513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106513.